Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV

[1]  R. Siliciano,et al.  Recommendations for measuring HIV reservoir size in cure-directed clinical trials , 2020, Nature medicine.

[2]  I. Sereti,et al.  Immunometabolism and HIV-1 pathogenesis: food for thought , 2020, Nature Reviews Immunology.

[3]  D. Speicher,et al.  The mitophagy effector FUNDC1 controls mitochondrial reprogramming and cellular plasticity in cancer cells , 2020, Science Signaling.

[4]  R. Siliciano,et al.  A unique viral reservoir landscape in HIV-1 elite controllers , 2020, Nature.

[5]  I. Vujkovic-Cvijin,et al.  HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases , 2020, Nature Communications.

[6]  M. Cruz-López,et al.  Nicotinamide reduces inflammation and oxidative stress via the cholinergic system in fructose-induced metabolic syndrome in rats. , 2020, Life sciences.

[7]  E. Pålsson-McDermott,et al.  Targeting immunometabolism as an anti-inflammatory strategy , 2020, Cell Research.

[8]  B. Berkhout,et al.  Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART. , 2020, JCI insight.

[9]  R. Diaz,et al.  Nicotinamide activates latent HIV-1 ex vivo in ART suppressed individuals, revealing higher potency than the association of two methyltransferase inhibitors, chaetocin and BIX01294 , 2020, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[10]  Yueping Shen,et al.  Application of metabolomics in the diagnosis of breast cancer: a systematic review , 2020, Journal of Cancer.

[11]  B. Sherman,et al.  Defective HIV-1 proviruses produce viral proteins , 2020, Proceedings of the National Academy of Sciences.

[12]  L. Montaner,et al.  Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. , 2020, AIDS.

[13]  N. Chandel,et al.  Mitochondrial TCA cycle metabolites control physiology and disease , 2020, Nature Communications.

[14]  M. Otto,et al.  A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease , 2019, Neurology and Therapy.

[15]  Jonathan Z. Li,et al.  Learning From the Exceptions: HIV Remission in Post-treatment Controllers , 2019, Front. Immunol..

[16]  B. Walker.  Faculty Opinions recommendation of A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[17]  B. Walker,et al.  Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. , 2019, The lancet. HIV.

[18]  E. Rodríguez-Gallego,et al.  Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection , 2019, EBioMedicine.

[19]  R. Siliciano,et al.  A novel quantitative approach for measuring the reservoir of latent HIV-1 proviruses , 2019, Nature.

[20]  L. Dodd,et al.  Increased Metabolic Activity on 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Human Immunodeficiency Virus–Associated Immune Reconstitution Inflammatory Syndrome , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  O. Sued,et al.  Induction of HIF-1α by HIV-1 Infection in CD4+ T Cells Promotes Viral Replication and Drives Extracellular Vesicle-Mediated Inflammation , 2018, mBio.

[22]  O. Pearce.  Cancer glycan epitopes: biosynthesis, structure and function. , 2018, Glycobiology.

[23]  J. Frater,et al.  Post-treatment and spontaneous HIV control , 2018, Current opinion in HIV and AIDS.

[24]  M. Lederman,et al.  HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers , 2018, The Journal of clinical investigation.

[25]  J. Routy,et al.  Plasma Indoleamine 2,3-Dioxygenase Activity Is Associated With the Size of the Human Immunodeficiency Virus Reservoir in Patients Receiving Antiretroviral Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  B. Walker,et al.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies , 2018, The Journal of infectious diseases.

[27]  R. Siliciano,et al.  HIV‐1 latent reservoir size and diversity are stable following brief treatment interruption , 2018, The Journal of clinical investigation.

[28]  Peter A. Calabresi,et al.  Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity , 2018, Science.

[29]  R. Vijay,et al.  Interleukin‐10 Directly Inhibits CD8+ T Cell Function by Enhancing N‐Glycan Branching to Decrease Antigen Sensitivity , 2018, Immunity.

[30]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[31]  G. Nolan,et al.  A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites , 2017, Nature.

[32]  S. Fortune,et al.  Beyond binding: antibody effector functions in infectious diseases , 2017, Nature Reviews Immunology.

[33]  David K. Finlay,et al.  Sugar or Fat?—Metabolic Requirements for Immunity to Viral Infections , 2017, Front. Immunol..

[34]  V. Salomaa,et al.  Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes , 2017, Diabetologia.

[35]  V. Annese,et al.  Metabolomic analysis with 1H-NMR for non-invasive diagnosis of hepatic fibrosis degree in patients with chronic hepatitis C. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[36]  R. Siliciano,et al.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. , 2017, Cell host & microbe.

[37]  C. Leslie,et al.  Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism , 2016, Science.

[38]  M. Gomez-Lazaro,et al.  Anti-inflammatory Chitosan/Poly-γ-glutamic acid nanoparticles control inflammation while remodeling extracellular matrix in degenerated intervertebral disc. , 2016, Acta biomaterialia.

[39]  Erdmann Rapp,et al.  Towards personalized diagnostics via longitudinal study of the human plasma N-glycome. , 2016, Biochimica et biophysica acta.

[40]  R. Siliciano,et al.  Defective proviruses rapidly accumulate during acute HIV-1 infection , 2016, Nature Medicine.

[41]  Marco Thomann,et al.  Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. , 2016, Molecular immunology.

[42]  J. van Grevenynghe,et al.  Current topics in HIV pathogenesis, part 2: Inflammation drives a Warburg-like effect on the metabolism of HIV-infected subjects. , 2016, Cytokine & growth factor reviews.

[43]  M. Perola,et al.  IgG Glycome in Colorectal Cancer , 2016, Clinical Cancer Research.

[44]  H. Hatano,et al.  Post-Treatment Controllers: Role in HIV “Cure” Research , 2016, Current HIV/AIDS Reports.

[45]  M. Lederman,et al.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption , 2015, AIDS.

[46]  J. Mullins,et al.  How Often does Treatment of Primary HIV Lead to Post-Treatment Control? , 2015, Antiviral therapy.

[47]  R. Phillips,et al.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.

[48]  H. Drummond,et al.  Inflammatory Bowel Disease Associates with Proinflammatory Potential of the Immunoglobulin G Glycome , 2015, Inflammatory Bowel Diseases.

[49]  Richard D Cummings,et al.  Protein glycosylation in cancer. , 2015, Annual review of pathology.

[50]  Susan R. Quinn,et al.  Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. , 2015, Cell metabolism.

[51]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[52]  M. Lederman,et al.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. , 2014, The Journal of infectious diseases.

[53]  Sarah Palmer,et al.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. , 2014, The lancet. HIV.

[54]  P. Ridker,et al.  A Novel Protein Glycan Biomarker and Future Cardiovascular Disease Events , 2014, Journal of the American Heart Association.

[55]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[56]  Anthony R Cillo,et al.  Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy , 2014, Proceedings of the National Academy of Sciences.

[57]  M. Troester,et al.  Metabolic Reprogramming of Macrophages , 2014, The Journal of Biological Chemistry.

[58]  Jae Ho Park,et al.  Poly-gamma-glutamic acid attenuates angiogenesis and inflammation in experimental colitis , 2013 .

[59]  A. Rudensky,et al.  Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation , 2013, Nature.

[60]  Sarah B. Laskey,et al.  Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure , 2013, Cell.

[61]  S. Merali,et al.  HIV-1 Vpr Modulates Macrophage Metabolic Pathways: A SILAC-Based Quantitative Analysis , 2013, PloS one.

[62]  Ryan D. Hernandez,et al.  Dysbiosis of the Gut Microbiota Is Associated with HIV Disease Progression and Tryptophan Catabolism , 2013, Science Translational Medicine.

[63]  Jae Ho Park,et al.  Poly-γ-Glutamic Acid Attenuates Angiogenesis and Inflammation in Experimental Colitis , 2013, Mediators of inflammation.

[64]  P. Gibbs,et al.  Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion , 2013, Molecular Cancer.

[65]  Oliver Sieber,et al.  Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion , 2013, Molecular Cancer.

[66]  J. Konopka.  N-Acetylglucosamine Functions in Cell Signaling , 2012, Scientifica.

[67]  M. Rosińska,et al.  Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2012, Archives of internal medicine.

[68]  P. Taylor,et al.  Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1 , 2012, Nature Medicine.

[69]  C. Rouzioux,et al.  Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy , 2012, Antiviral therapy.

[70]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[71]  S. Deeks,et al.  Public health: Towards a cure for HIV , 2012, Nature.

[72]  T. Osaki,et al.  Suppressive Effects of N-Acetyl-d-Glucosamine on Rheumatoid Arthritis Mouse Models , 2012, Inflammation.

[73]  T. Osaki,et al.  Suppressive Effects of N-Acetyl-d-Glucosamine on Rheumatoid Arthritis Mouse Models , 2012, Inflammation.

[74]  S. Kreth,et al.  Selection of reliable reference genes for quantitative real-time PCR in human T cells and neutrophils , 2011, BMC Research Notes.

[75]  R. Schooley,et al.  AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. , 2010, The Journal of infectious diseases.

[76]  B. Scallon,et al.  Engineering host cell lines to reduce terminal sialylation of secreted antibodies , 2010, mAbs.

[77]  Jeff E. Mold,et al.  Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease , 2010, Science Translational Medicine.

[78]  E. Rosenberg,et al.  Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection , 2010, PLoS ONE.

[79]  M. Hirsch,et al.  Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment , 2009, AIDS.

[80]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[81]  T. Rutigliano,et al.  A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load , 2008, Nature Protocols.

[82]  D. Havlir,et al.  Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. , 2007, The Journal of infectious diseases.

[83]  S. Iida,et al.  Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. , 2007, Molecular immunology.

[84]  Richard O'Kennedy,et al.  Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. , 2007, Drug discovery today.

[85]  J. van Lunzen,et al.  Virological rebound and its consequences during treatment interruption , 2007, Current opinion in HIV and AIDS.

[86]  J. Lawrence,et al.  A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). , 2006, The Journal of infectious diseases.

[87]  Y. Kooyk,et al.  Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45 , 2006, Nature Immunology.

[88]  V. Johnson,et al.  Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. , 2006, The Journal of infectious diseases.

[89]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[90]  Mary K. Lewinski,et al.  Genome-Wide Analysis of Chromosomal Features Repressing Human Immunodeficiency Virus Transcription , 2005, Journal of Virology.

[91]  L. Montaner,et al.  Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection , 2004, PLoS medicine.

[92]  M. Desvarieux,et al.  Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection. , 2004, The Journal of infectious diseases.

[93]  K. Ley.  The role of selectins in inflammation and disease. , 2003, Trends in molecular medicine.

[94]  E. Verdin,et al.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.

[95]  M. Knuuttila,et al.  Metabolic Control as a Modifier of the Association between Salivary Factors and Dental Caries among Diabetic Patients , 2003, Caries Research.

[96]  J. Nicholson,et al.  Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.

[97]  S. Salvatore,et al.  A pilot study of N‐acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease , 2000, Alimentary pharmacology & therapeutics.

[98]  I. Finnie,et al.  Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. , 1995, The Journal of clinical investigation.

[99]  G. Lauc,et al.  Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis , 2019, Current HIV/AIDS Reports.

[100]  D. Richman,et al.  Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. , 2018, AIDS.

[101]  P. Bernini,et al.  Metabolomic analysis with 1 H-NMR for non-invasive diagnosis of hepatic fibrosis degree in patients with chronic hepatitis C , 2017 .

[102]  D. Blacker.  Food for thought. , 2013, JAMA neurology.

[103]  E. Verdin,et al.  In vivo, in vitro, and in silico analysis of methylation of the HIV-1 provirus. , 2011, Methods.

[104]  A. Kuno,et al.  A versatile technology for cellular glycomics using lectin microarray. , 2010, Methods in enzymology.

[105]  C. Lebrilla,et al.  A glycomics approach to the discovery of potential cancer biomarkers. , 2010, Methods in molecular biology.

[106]  B. Scallon,et al.  Fc Glycans Terminated with N‐Acetylglucosamine Residues Increase Antibody Resistance to Papain , 2007, Biotechnology progress.

[107]  C. Taylor,et al.  An antitumor antibody in normal human serum: reaction of anti-T with breast carcinoma cells. , 1980, Oncology.

[108]  C. Taylor,et al.  An Antitumor Antibody in Normal Human Serum , 1980 .